# SUPERGEN

## BUILDING FOR GROWTH

04 ANNUAL REPORT

**Cautionary Statement Regarding Forward-Looking Statements:** This Annual Report contains predictions, estimates and other forward-looking statements that involve a number of risks and uncertainties about our business, including, but not limited to, our expectation that the FDA will provide a decision on our NDA for Dacogen during the third quarter of 2005; our belief that Dacogen will be approved and commercialized in both the U.S. and the E.U.; our belief that EuroGen will launch its first product, Nipent, in five major E.U. markets during 2005; our expectation that Nipent will contribute substantially to our revenues in 2005; our expectation that Paclitaxel will receive approval in the E.U. during 2005; and our expectation that we will select one or more new compounds for in-licensing by mid-year 2005. In some cases, these forward-looking statements may be identified by the usage of words such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of such words and other similar terminology. While this discussion represents our current judgment on the future direction of our business, these statements involve known and unknown risks and uncertainties that may cause our or our industry's results, level of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Certain unknown or immaterial risks and uncertainties can also affect our forward-looking statements. Forward-looking statements not specifically described above also may be found in other sections of this report. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For a discussion of the known and material risks that could affect our actual results, please see "Factors Affecting Future Operating Results" in this Annual Report.

SUPERGEN

# BUILDING FOR GROWTH

SuperGen is dedicated to serving the needs of oncology and hematology patients worldwide. In order to accomplish this mission, our corporate infrastructure must be capable of supporting both current and future products through clinical development, regulatory review and commercialization. Our future growth depends on a solid product portfolio, sustainable revenue streams, strategic partnerships and a secure financial position. Throughout 2004, our energies were focused on implementing measures and activities that will make SuperGen a stronger company from the inside out. In this year's annual report, we are pleased to share with you how SuperGen is "Building for Growth," through strategic actions designed to enhance our infrastructure and ultimately increase value for our stockholders.


SIGNED EXCLUSIVE LICENSE AGREEMENT WITH MGI PHARMA
PREPARED FOR EUROPEAN PRODUCT LAUNCH
ACCELERATED REGULATORY FILINGS FOR DACOGEN & ORATHECIN
FILED TWO NDAs
BUILDING FOR GROWTH
FILED TWO MAAs
LAUNCHED ONCOLOGY ALLIANCE NETWORK
STRENGTHENED FINANCIAL CONDITION
EXPANDED EUROGEN OPERATIONS



# DEAR STOCKHOLDER,

By any measure, 2004 was a dynamic year for SuperGen. Significant progress was made in positioning our company for future growth. Despite some challenges, we remained focused on our strategic objectives and implemented the measures necessary to transition from our foundation as a drug development company to a viable commercial enterprise serving hematology and oncology patients. Much work still needs to be done, but SuperGen enters the new year stronger — organizationally, commercially and financially — and eager to move forward.

## ENSURING FUTURE REVENUE WITH A TRANSFORMING DEAL

In September 2004, we announced an exclusive worldwide licensing agreement with MGI PHARMA for the further development and commercialization of Dacogen™ (decitabine) injection, our investigational anticancer therapeutic for the treatment of myelodysplastic syndromes (MDS). This deal truly transformed SuperGen and is expected to be a significant driver of our future growth.

MGI's belief in Dacogen's potential is reflected in the terms of our agreement. MGI's $40 million equity investment at $10 per share represented approximately a 56 percent premium to SuperGen's market price at the time of the deal. MGI also committed to spend a minimum of $15 million on future development of Dacogen, and SuperGen will receive up to an additional $45 million, based on completion of specific regulatory and commercialization milestones. Several of these milestones were achieved during 2004, and we will potentially earn up to $25 million in milestone payments during 2005. Most importantly, assuming we receive requested regulatory approvals for Dacogen, SuperGen will receive a continuing revenue stream from Dacogen royalties for all indications, at a rate of 20 percent escalating up to 30 percent, based on worldwide sales for the life of the 20-year agreement.

We believe MGI is the right partner for Dacogen, with financial resources and commercial infrastructure that will ensure more rapid penetration of the MDS market and expand development for additional indications. MGI plans to initiate a Phase III trial of Dacogen for the treatment of acute myelogenous leukemia (AML) in early 2005 and will evaluate its potential for use outside of MDS and AML.

## PLACING A PRIORITY ON REGULATORY PROGRESS

Accelerating our regulatory filings for both Dacogen and Orathecin™ (rubetican) capsules was a key strategic objective during 2004. SuperGen submitted two New Drug Applications (NDAs) with the United States (U.S.) Food and Drug Administration (FDA) and two Marketing Authorization Applications (MAAs) with the European Agency for the Evaluation of Medicinal Products (EMEA) for Dacogen and Orathecin respectively, through our subsidiary, EuroGen Pharmaceuticals Limited.

The Dacogen NDA was submitted to the FDA early in the fourth quarter and accepted for review on December 31, 2004. We anticipate the FDA's decision during the third quarter of 2005. Our MAA was accepted by the EMEA for review in late October 2004, and a decision on the European filing for Dacogen should come within the same time period as the FDA decision.

SuperGen withdrew its U.S. NDA for Orathecin on December 30, 2004. This NDA was originally submitted to the FDA on January 26, 2004, with a target Prescription Drug User Fee Act (PDUFA) date of November 26, 2004. During the fourth quarter, at the FDA's request, SuperGen submitted additional clinical data from a trial of Orathecin as a first-line treatment for pancreatic cancer, as well as new analyses of data from the studies in second- and third-line patients. These data were classified as a major amendment by the FDA, triggering an extension of the review period and moving the PDUFA date to February 26, 2005.

Withdrawing the Orathecin NDA at this advanced stage of the regulatory process was not an easy decision, but we believe it was in the best interest of SuperGen and our stockholders. Initial feedback from the FDA and our external consultants indicates that the current data will not support the approval of Orathecin as a single agent in refractory patients. The NDA included data on 1,900 pancreatic cancer patients, and we continue to believe that Orathecin has clinical utility. Hopefully, we will learn more from the FDA's report on its review, which we just received in early 2005 and are beginning to analyze.

From a clinical perspective, Orathecin may have better prospects for approval in the U.S. as a combination therapy. Preliminary studies using Orathecin as a single agent clearly demonstrate activity, and our recently completed Phase I work in refractory cancer patients produced objective response rates and disease stabilization. Based on these results, SuperGen is proceeding with the non-randomized portion of our planned Phase III trial of Orathecin in combination with gemcitabine, which started in early 2005. Beyond that, we will determine the feasibility of pursuing further U.S. development based on what we learn from the FDA report.

We think our action regarding the U.S. NDA for Orathecin has absolutely no effect on the status of our European filing. We remain confident that our randomized study in second- and third-line patients showed a benefit in those who received Orathecin. We are optimistic that we have provided sufficient information to the EMEA to be persuasive.

## CONSOLIDATING OUR INFRASTRUCTURE FOR COMMERCIALIZATION

SuperGen underwent a substantial reorganization in 2004, restructuring several departments, consolidating management functions, creating more rational, efficient and responsive decision-making processes and downsizing our workforce by approximately 15 percent. This effort included establishing an internal Business Development Advisory Committee to identify potential products for in-licensing or acquisition. Approximately 30 "Best in Class" late Phase II hematological and/or oncological drugs have already been screened, and several candidates have been selected for further review by senior management. This is an active, ongoing and dynamic process.

Corporate governance was a key initiative in 2004, and we are developing a system of checks and balances that we expect will enhance our ability to meet the growing demands on publicly traded companies like us within the new regulatory environment as influenced by the Sarbanes-Oxley Act.

We also strengthened our management ranks by adding and promoting key individuals. Wayne Davis, Vice President for Clinical Operations, was hired to solidify internal clinical capabilities and Joi Ninomoto was promoted to Vice President, Medical Affairs to recognize her excellence in developing a "Best in Class" Medical Affairs group. Both of these individuals have made valuable contributions since joining SuperGen and we are pleased to have them on our team.

## STRENGTHENING OUR FINANCIAL CONDITION

SuperGen ended the year with an improved financial position, with $57 million in operating cash, which included $40 million from MGI's equity investment. Strict adherence to our budgeting discipline resulted in an average quarterly net cash burn rate of approximately $6 million, a major accomplishment considering we completed four regulatory filings this year.

Our financial performance was challenged by Medicare price rollbacks, which negatively impacted Nipent® (pentostatin for injection) sales in the U.S. during the first half of the year. SuperGen's dedicated sales and marketing team was able to reverse this trend by working directly with our physician network. The impressive recovery in Nipent revenues, which increased from $0.7 million in the first quarter of 2004 to approximately $5 million in the fourth quarter, is due to their diligent efforts.

During 2005, we anticipate that Dacogen will be approved and commercialized in both the U.S. and the European Union (E.U.), and these events will trigger up to $25 million in additional milestones to SuperGen before year-end. If Dacogen is approved during the third quarter, SuperGen could begin receiving royalties from sales during 2005.

## FACING THE CHALLENGES & SEIZING THE OPPORTUNITIES

While prospects for Orathecin remain uncertain at this time, our strategic plan has always assumed we would need to grow our product pipeline through in-licensing or acquisition. Several strong candidates have emerged from our extensive screening process, and we expect to select one of these during 2005. Most likely, this will be a late Phase II or Phase III product, but we will also consider marketed products and platform technologies that have produced solid product candidates.

We have exciting plans for our European subsidiary during 2005. EuroGen will launch its first commercial product, Nipent, in at least five major E.U. markets. Nipent has recently generated renewed interest in the hematology community as the subject of several published scientific studies that examine its activity in treating Chronic Lymphocytic Leukemia (CLL), as well as Graft versus Host Disease (GvHD). The promising data generated by these studies contribute to a growing body of scientific evidence on Nipent's utility, which suggests continued sales momentum during the coming year.

## BUILDING FOR FUTURE GROWTH

My first year as your president and chief executive officer has been both demanding and exciting. Building a global pharmaceutical company is an ambitious goal that takes time and patience. Thanks to a truly extraordinary team of dedicated and talented people, SuperGen has made remarkable progress this year, putting in place the strategic, financial and operational elements that I believe will enable us to grow in the years ahead. I am proud of all we have accomplished and personally grateful for the support of our employees, our Board of Directors and our stockholders. We can look forward to our future with confidence.

Sincerely,

James S. J. Manuso, Ph.D.
President and Chief Executive Officer


RAISED $74 MILLION

EXPANDED SALES EFFORTS

INCREASED NIPENT REVENUES

SECURED EQUITY INVESTMENT, MILESTONES & FUTURE ROYALTIES FROM MGI PHARMA

REINFORCING OUR CAPITAL BASE – SuperGen needs a secure financial foundation to fund its growth. In 2004, our strategic plans included four regulatory filings for our two lead product candidates and development of the commercial and marketing infrastructure necessary for a successful launch upon approval. During the first quarter, we raised $34 million through a private placement to address these near-term objectives. We realized, however, that our vision of building a viable company demanded a more secure financial profile.

# STRENGTHENED

## OUR FINANCIAL CONDITION

Several measures implemented during 2004 reinforced the existing financial foundation by increasing SuperGen's capital resources, bolstering our financial position, managing operational expenses and enhancing and establishing new sources of revenue. Consequently, SuperGen can fund reasonable levels of clinical development for future products and can continue to drive its business development plans with confidence.

### SECURING A STRONG STRATEGIC COLLABORATION

Most significantly, we granted an exclusive license to MGI for the development and commercialization of Dacogen. This agreement transformed our financial position by strengthening the balance sheet with a $40 million equity infusion and providing access to up to an additional $45 million in cash payments upon completion of specific regulatory and commercialization milestones. SuperGen has already achieved several of these milestones, earning $12.5 million from MGI in 2004, and we will potentially receive up to another $25 million in milestones during 2005. MGI has committed to funding the future development of Dacogen with a minimum of $15 million, ensuring that appropriate resources are committed to move Dacogen forward in additional indications. SuperGen will receive royalties from Dacogen starting at 20 percent and increasing to 30 percent, based on worldwide sales. If Dacogen is approved this year, the new revenue stream could begin contributing to our bottom line during 2005.

### EXPANDING SALES EFFORTS

SuperGen also focused on increasing sales during 2004. Nipent sales experienced pressure from Medicare price rollbacks during the first half of the year. We were able to reverse this trend by expanding direct outreach to our physician network and implementing targeted regional programs on reimbursement issues and procedures. Our efforts resulted in consecutive quarterly sales increases throughout 2004, with Nipent net sales rising from $0.7 million in the first quarter to $5 million in the fourth quarter.

### IMPLEMENTING BETTER CONTROLS

We instituted stronger financial controls over our operations, which reduced the risk of premature operational and capital expenditures and enabled us to keep our burn rate on target. New cost-benefit analysis procedures ensure that we allocate our financial resources for new products wisely in advance of full commercialization and marketing activities. Each of these measures taken during 2004 has helped us attain a new level of fiscal strength and financial discipline that will allow SuperGen to focus on reaching long-term profitability.

PREPARING THE FOUNDATION – SuperGen established an international commercialization plan in 2004 to support the potential of two product approvals, Dacogen and Orathecin, within a one-year time frame in both the United States and Europe. Additionally, we planned to assume responsibility for European sales, marketing and distribution activities of Nipent. Our plan assembled the structural elements required for launching our products in five key E.U. markets.

# A CORPORATE INFRASTRUCTURE THAT PAVES THE ROAD TO COMMERCIALIZATION

## FRAMING OUR KEY AUDIENCES

SuperGen's commercialization team developed an extensive program of 12 Scientific Advisory Boards (SABs), held across the U.S. market. Awareness of Dacogen as an MDS therapeutic agent increased substantially among leading cancer specialists as a result of these SABs. Structured as professional forums for the exchange of scientific and clinical information, these meetings allowed us to initiate a valuable dialogue and build our brand with hundreds of physicians. They generated insights that will frame the product marketing campaigns for Dacogen and Orathecin, if approved.

Most significantly, we launched an oncology alliance network in cooperation with Pharmatech and ION, two leading oncology organizations. This major initiative allows us access to more than 6,000 oncologists who will purchase products directly, attend marketing events and clinical forums and participate as investigators on cooperative trials. This network is a valuable asset that we expect will be vital to our long-term success.

Our 2005 Compassionate Use Program and Launch Plan for Orathecin was also completed during 2004 in anticipation of the original PDUFA date during the fourth quarter. We believe the subsequent withdrawal of our U.S. NDA filing at year-end has no bearing on our regulatory filing in Europe, and Orathecin remains on track for regulatory review by the EMEA during 2005.

## MOBILIZING FOR MANUFACTURING

Another important piece of the infrastructure was assembling demonstration and scale-up batches of Dacogen, as well as clinical supplies of Orathecin for both the U.S. and E.U. For Nipent, several quality assurance and quality control audits pertaining to manufacturing were completed, distribution procedures for contract manufacturers were established, and we strengthened our patent portfolio with regard to Nipent manufacturing processes.

## EXTENDING INDICATIONS

We also commenced Phase IV Nipent post-marketing trials in GvHD, both in children and adults, CLL and low-grade lymphoma. These studies are accumulating clinical data that we expect will demonstrate Nipent's utility in other treatment regimens. A full cost and clinical benefit analysis was completed, and we are exploring the feasibility of converting the Phase IV post-marketing trials to a registration trial during 2005.

## REMODELING & RENEWING OUR PIPELINE

As 2004 drew to a close, SuperGen anchored its commercialization scaffold by finalizing the Dacogen exclusive licensing agreement with MGI. As the agreement required, Dacogen manufacturing operations were transitioned to MGI during the fourth quarter. SuperGen is proud of our collaboration with MGI. We strongly believe that we forged the right partnership with the right company, which will provide an efficient path to market for Dacogen. SuperGen enters the new year ready and able to grow its pipeline by acquiring, developing and commercializing promising new products.

LAUNCHED ONCOLOGY ALLIANCE NETWORK WITH PHARMATECH & ION

COMPLETED MANUFACTURING & DISTRIBUTION PROCEDURES


EUROGEN: U.K.
NIPENT®
PACLITAXEL
GERMANY
FRANCE
ITALY

EXTENDING SALES AND MARKETING REACH – SuperGen's long-term growth depends in part on our ability to extend our sales and marketing operations beyond the United States. A European presence is a necessary and critical component of SuperGen's strategy to become a truly global pharmaceutical company. Our subsidiary, EuroGen, manages the development of our commercial operations in key European markets and aggressively seeks opportunities to in-license new products that will expand SuperGen's product pipeline.

# EXPANSION

## OF EUROGEN TO BROADEN MARKET REACH

### MANAGING REGULATORY FILINGS & MARKETING RIGHTS

EuroGen's activities during 2004 centered on preparing and submitting MAAs for both Orathecin and Dacogen with the EMEA. Both filings were accepted for review, and decisions on these two products are anticipated during 2005. Under the terms of our exclusive licensing agreement with MGI, EuroGen is the primary interface with the EMEA and will manage the remaining stages of the approval process for Dacogen.

In addition, during 2004 SuperGen reacquired the rights to market Nipent outside of the U.S. from Pfizer. By mid-year 2005, EuroGen should assume responsibility for all sales, marketing and distribution of Nipent from Pfizer's marketing partner, Wyeth Pharmaceuticals. Nipent will be EuroGen's first product launch in Europe during the summer of 2005.

### SUPPORTING OUR COMMERCIALIZATION IN EUROPEAN MARKETS

EuroGen dedicated much of 2004 to improving its marketing infrastructure. We identified and selected specific European countries as our primary sales territories, representing up to 80 percent of the potential sales volume for our products. Initially, EuroGen will market SuperGen's products directly to cancer centers of excellence in the United Kingdom, France, Germany and Italy. EuroGen has already begun the process of assembling a small, highly select team of pharmaceutical sales representatives with significant oncology and hematology experience in these primary markets. During 2005, EuroGen plans to expand its operations to Spain, Austria and Ireland and establish a network of independent distributors to promote the sales of its products in other European countries.

### LEVERAGING OUR INVESTMENT FOR FUTURE GROWTH

Considerable energy and resources have been spent building EuroGen this year, but we believe we can leverage this investment to yield important growth opportunities for SuperGen. With an established European sales and marketing infrastructure, we believe SuperGen is an attractive marketing partner for smaller pharmaceutical companies seeking a commercial presence in this region. As an extension of SuperGen's business development operations, EuroGen can actively seek to in-license new products for development, including those specifically targeted for European markets. EuroGen strengthens our foundation and expands our market reach, creating new opportunities to grow our product pipeline.

A FOCUSED MISSION – Developing and commercializing new cancer treatments is our mission. SuperGen's corporate strategy is to license or acquire rights to late-stage compounds that have already shown efficacy in humans within a particular disease. By doing so, we can control time and expense associated with drug commercialization, focus our energy on optimizing drug performance and deliver that drug to patients in need.

# BUILDING

## A PRODUCT PORTFOLIO ENGINEERED FOR GROWTH

### A GROWING REVENUE STREAM FROM IN-LICENSED COMPOUNDS

At the bedrock of SuperGen's portfolio are products that penetrate the oncology and hematology markets. Mitomycin, Nipent and Surface Safe® are all in-licensed or developed compounds contributing to our current revenue stream. During 2004, interest increased in Nipent's utility for treatment of GvHD in both child and adult bone marrow transplant patients. Growing demand and higher product pricing increased Nipent revenues by 16 percent. With the transfer of marketing rights to SuperGen and a European launch planned for summer of 2005, we expect Nipent to contribute substantially to SuperGen's revenues in the coming year.

### AN EVOLVING PRODUCT PIPELINE

In 2004, we filed NDAs for two investigational cancer therapeutics, Dacogen for MDS and Orathecin for advanced pancreatic cancer, with the FDA. We also filed MAAs with the EMEA for regulatory approval in the E.U.

However, based on feedback from the FDA, SuperGen withdrew its NDA for Orathecin at year-end. Upon review of the FDA's full report, we will decide on the future development of Orathecin in the U.S. Orathecin is still scheduled for review by the EMEA during 2005.

Additionally, Paclitaxel, our generic equivalent to Taxol®, a widely used cancer therapeutic, received U.S. approval in 2004 and European approval is expected in 2005. SuperGen does not intend to market Paclitaxel in the U.S., but through EuroGen, we will market Paclitaxel in Europe upon approval.

### PARTNERING TO OPTIMIZE COMMERCIALIZATION

During the third quarter, we granted MGI an exclusive license to Dacogen to ensure that this drug will reach the market as expeditiously as possible. Importantly, MGI has committed to fund further development costs of Dacogen for additional indications. Milestone payments and future royalties from Dacogen will support SuperGen's continued effort to develop new and exciting cancer treatments.

### TRANSFORMING THE COMPANY THROUGH IN-LICENSING & ACQUISITIONS

We have begun the process of expanding our product pipeline. A rigorous screening of more than 30 new product candidates has identified several leading compounds for potential in-licensing, and we expect to select one or more for development by mid-year 2005. While we have focused primarily on therapeutic products, we will also consider drug delivery platform technologies that would complement SuperGen's product portfolio.

Developing a solid product portfolio that can generate consistent revenues takes patience. SuperGen's commitment remains steadfast to build a strong portfolio of oncology and hematology products and deliver value to our stockholders.


NIPENT®
DACOGEN™
MITOMYCIN
ORATHECIN™
PACLITAXEL
SURFACE SAFE®

# PRODUCT PIPELINE



# IN SUMMARY

Today, SuperGen is quite different from the company we were just a short year ago. The internal improvements we made to our organization, our processes, and our commercial practices during 2004 reinforced our foundation, moved our products closer to market and sharpened our focus. Collectively, we believe these changes have made us a stronger company.

SuperGen is now capable of supporting future growth because our finances are sound. We raised capital, eliminated all balance sheet debt, implemented better cost controls and expanded our sales efforts. We structured a strategic partnership with financial terms that provide both milestone payments and a royalty revenue stream upon product commercialization, which will sustain us as we continue to build our revenue base.

SuperGen's commercialization infrastructure can now effectively execute strategic marketing programs because we installed the proper key structural elements. We developed our primary audience and customer base, refined our manufacturing protocols, mobilized our distribution networks and strengthened our patent portfolio.

SuperGen now has even broader market reach through EuroGen, which is building a carefully selected marketing team and distribution network that will be ready to support commercialization of our products, as well as those of other companies in several major European markets.

Throughout this report, we have shown some of the ways in which we have been "Building for Growth." We believe this ongoing process is the path to realizing our most important goals. With a sound infrastructure that will enable us to continue to grow, we believe we can succeed in improving patients' lives and delivering value to our stockholders.



# FINANCIALS 04

SUPERGEN

# STOCKHOLDER INFORMATION

## BOARD OF DIRECTORS

James S. J. Manuso, Ph.D.
*Chairman, President and Chief Executive Officer SuperGen, Inc.*

Charles J. Casamento
*Chief Executive Officer Osteologix, Inc.*

Thomas V. Girardi
*Senior Partner Girardi & Keese*

Allan R. Goldberg, Ph.D.
*Managing Partner The Channel Group LLC*

Walter J. Lack
*Managing Partner Engstrom, Lipscomb & Lack*

Michael D. Young, M.D., Ph.D.
*Chairman and Chief Scientific Officer Strategic Healthcare Development, LLC*

## SENIOR MANAGEMENT TEAM

James S. J. Manuso, Ph.D.
*President and Chief Executive Officer*

Edward L. Jacobs
*Chief Operating Officer*

Michael Molkentin
*Chief Financial Officer and Corporate Secretary*

Audrey Jakubowski, Ph.D.
*Chief Regulatory and Quality Affairs Officer*

Wayne Davis, Ph.D.
*Vice President, Clinical Operations*

Timothy L. Enns
*Senior Vice President, Corporate Communications and Business Development*

Larry Johnson
*President and Chief Executive Officer, EuroGen Pharmaceuticals Limited (United Kingdom)*

Robert Marshall
*Vice President, Sales*

Michael V. McCullar, Ph.D.
*Vice President, Strategic Planning and Development*

Joi Ninomoto, Pharm.D.
*Vice President, Medical Affairs*

Sanjeev Redkar, Ph.D.
*Vice President, Manufacturing and Preclinical Development*

## CORPORATE HEADQUARTERS

SuperGen, Inc.
4140 Dublin Blvd.
Suite 200
Dublin, CA 94568
925.560.0100 Tel
925.560.0101 Fax

EuroGen Pharmaceuticals Limited
1st Floor
Eagle Tower
Montpellier Drive
Cheltenham, Gloucestershire
GL51 1TA
United Kingdom
Phone: +44 (0) 1242-703646

## INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Ernst & Young
Building 1, Suite 200
1001 Page Mill Road
Palo Alto, CA 94304

## LEGAL COUNSEL

Wilson Sonsini Goodrich & Rosati
650 Page Mill Road
Palo Alto, CA 94304
650.493.6811 Tel

## TRANSFER AGENT

Mellon Investor Services, LLC
Overpeck Center
85 Challenger Road
Ridgefield Park, NJ 07660
800.522.6645 Tel
www.melloninvestor.com

## ANNUAL MEETING

The annual meeting of stockholders will be held May 12 at 2 p.m., at SuperGen's corporate headquarters.

## NASDAQ: SUPG

For information about the company, stockholders and other interested parties may contact the Investor Relations Department at the company headquarters, or visit the company website at www.supergen.com. Inquiries regarding stock certificates, transfer requirements, address changes, and related matters should be directed to the Transfer Agent at the address given above.

DESIGN: BLUERAE CREATIVE, BOSTON, MA

SuperGen®